We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cilansetron.
- Authors
Zimmermann, Anthony E.
- Abstract
If approved, cilansetron (Calmactin, Solvay Pharmaceuticals) would be the second selective 5-HT antagonist introduced for the treatment of imtable bowel syndrome (IBS). Based on 2 main clinical trials, cilansetron 2 mg orally 3 times daily appears to be effective in the relief of IBS-D symptoms (abdominal pain/discomfort) and abnormal bowel habits in both male and female patients. Adverse effects were minor, with constipation being the most commonly reported adverse effect. No information is currently available on cilansetron's potential for drug interactions, need for dose adjustments in renal or hepatic insufficiency, long-term safety, or cost. Cilansetron was granted priority review status by FDA on September 1, 2004, for the treatment of diarrhea predominant IBS in men and women. Currently marketed agents for the treatment of IBS are only approved for use in female patients. INSET: Formulary considerations.
- Subjects
SEROTONIN antagonists; SOLVAY Pharmaceuticals Inc.; CLINICAL trials; IRRITABLE colon treatment; PHARMACEUTICAL industry
- Publication
Formulary, 2005, Vol 40, Issue 2, p44
- ISSN
1082-801X
- Publication type
Article